Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms

被引:17
作者
El-Sayed, A. [1 ]
机构
[1] Cairo Univ, Dept Med & Infect Dis, Fac Vet Med, Giza, Egypt
关键词
Bat lyssavirus; Biting; Rabies; SAG1; Treatment; Vaccine;
D O I
10.1016/j.ijvsm.2018.05.001
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Rabies is a vaccine-preventable fatal disease in man and most mammals. Although rabies is recorded in 150 territories and is responsible for at least 60,000 human deaths every year worldwide, it is a neglected tropical problem. Most of the rabies free countries are considered to be fragile free as the disease may re-emerge easily through wild mammals. For the performance of effective rabies eradication programs, a complex set of strategies and activities is required. At the time, a joint project of WHO-OIE-FAO which was announced in 2015, plans to control animal-human-ecosystems rabies interface. For effective rabies control, prophylactic policies must be applied. These include various educational outreaches for farmers and people living in endemic areas, enforced legislation for responsible dog ownership, control programs for the free-ranging stray dog and cat populations, field large-scale vaccination campaigns, and the development of new vaccine delivery strategies for both humans and animals. The present work presents the advances in the development of new safe, effective and economic vaccines for domestic dogs, and oral vaccines for the control of the disease in wild animals. It presents also some therapeutic protocols used for the treatment of patients.
引用
收藏
页码:8 / 15
页数:8
相关论文
共 92 条
[1]   Rabies transmission risks during peripartum - Two cases and a review of the literature [J].
Aguemon, Christiane Tshabu ;
Tarantola, Arnaud ;
Zoumenou, Eugene ;
Goyet, Sophie ;
Assouto, Pamphile ;
Ly, Sowath ;
Mewanou, Serge ;
Bourhy, Herve ;
Dodet, Betty ;
Aguemon, Abdou-Rahmann .
VACCINE, 2016, 34 (15) :1752-1757
[2]   A New Rabies Vaccine Based on a Recombinant Orf Virus (Parapoxvirus) Expressing the Rabies Virus Glycoprotein [J].
Amann, Ralf ;
Rohde, Joerg ;
Wulle, Ulrich ;
Conlee, Douglas ;
Raue, Rudiger ;
Martinon, Olivier ;
Rziha, Hanns-Joachim .
JOURNAL OF VIROLOGY, 2013, 87 (03) :1618-1630
[3]  
Amarasinghe G, 2018, ARCH VIROL, DOI [10.1007/s00705-018-3814-x, DOI 10.1007/S00705-018-3814-X.]
[4]   Generation of recombinant rabies viruses encoding NanoLuc luciferase for antiviral activity assays [J].
Anindita, Paulina Duhita ;
Sasaki, Michihito ;
Nobori, Haruaki ;
Sato, Akihiko ;
Carr, Michael ;
Ito, Naoto ;
Sugiyama, Makoto ;
Orba, Yasuko ;
Sawa, Hirofumi .
VIRUS RESEARCH, 2016, 215 :121-128
[5]  
[Anonymous], 2017, WILDL RES RAB
[6]  
[Anonymous], 1998, WHO REPORT
[7]  
[Anonymous], 2017, FAO OIE WHO ENL THEI
[8]   Antiviral therapy for human rabies [J].
Appolinario, Camila M. ;
Jackson, Alan C. .
ANTIVIRAL THERAPY, 2015, 20 (01) :1-10
[9]   Novel Lyssavirus in Bat, Spain [J].
Arechiga Ceballos, Nidia ;
Vazquez Moron, Sonia ;
Berciano, Jose M. ;
Nicolas, Olga ;
Aznar Lopez, Carolina ;
Juste, Javier ;
Rodriguez Nevado, Cristina ;
Aguilar Setien, Alvaro ;
Echevarria, Juan E. .
EMERGING INFECTIOUS DISEASES, 2013, 19 (05) :793-795
[10]   POTENTIAL PATHOGENICITY FOR RODENTS OF VACCINES INTENDED FOR ORAL VACCINATION AGAINST RABIES - A COMPARISON [J].
ARTOIS, M ;
GUITTRE, C ;
THOMAS, I ;
LEBLOIS, H ;
BROCHIER, B ;
BARRAT, J .
VACCINE, 1992, 10 (08) :524-528